Search results for " Combination"

showing 10 items of 923 documents

Acute renal insufficiency and pancreatitis in a child with atypical Henoch–Schönlein purpura: efficacy of a single dose of cyclophosphamide

2018

A 9-year-old boy with petechiae on the legs and abdominal pain was unsuccessfully treated with steroids. He was admitted to our hospital for the onset of fever, ecchymosis, and arthralgia. Skin lesions suggested vasculitis, but they were not typical of Henoch–Schönlein purpura. He showed ecchymosis of the scrotal bursa, diffusion of petechiae to the trunk and arms, vomiting, severe abdominal pain, oliguria with hyponatremia, hypoalbuminemia, low C3 levels, high levels of creatinine, blood urea nitrogen, and tubular enzymes, proteinuria, and glycosuria. The urinary sediment showed macrohaematuria, and hyaline and cellular casts. Ultrasound showed polyserositis. He was treated with intraveno…

MalecorticosteroidMedicine (General)medicine.medical_specialtyAbdominal painHenoch-Schonlein purpuraIgA VasculitisEcchymosisAnti-Inflammatory Agentspancreatitisskin lesionCase ReportsMethylprednisoloneBiochemistryGastroenterology03 medical and health sciencesR5-9200302 clinical medicinehemic and lymphatic diseases030225 pediatricsInternal medicinemedicineHumansChildbusiness.industryBiochemistry (medical)pancreatitiAcute renal insufficiencyCell BiologyGeneral MedicineAcute Kidney InjuryPrognosismedicine.diseasePurpuraMethylprednisolonePancreatitisAcute pancreatitisDrug Therapy Combinationcyclophosphamide030211 gastroenterology & hepatologymedicine.symptomHenoch–Schönlein purpuraHyponatremiabusinessImmunosuppressive Agentsmedicine.drugJournal of International Medical Research
researchProduct

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct

Topical allopurinol or corticosteroids and acetylcysteine in the early treatment of experimental corneal alkali burns: a pilot study.

2002

PURPOSE. To investigate the effect of topical allopurinol on experimental corneal burns and to compare this to established treatment modalities such as topical prednisolone and acetylcysteine. METHODS. Twenty Wistar rats were randomly assigned to four groups (n=5 each). The groups were controls (normal saline), allopurinol 0.4% eye drops, prednisolone acetate 1% eye drops and acetylcysteine 8% eyedrops. Corneal burn was induced using a 3 mm paper disc soaked in 1N NaOH for 60 seconds. Drops were instilled 6 times per day. In addition, one drop/day ofloxacine was given to prevent secondary infections. Eyes were enucleated 50 hours later and fixed in 4.5% formaldehyde. Three histological leve…

Malemedicine.drug_classmedicine.medical_treatmentSecondary infectionAdministration TopicalAllopurinolPrednisoloneChemical burnAnti-Inflammatory AgentsAllopurinolPilot Projects030204 cardiovascular system & hematologyAlkalies03 medical and health sciencesCorneal Burn0302 clinical medicineCorneaBurns ChemicalMedicineAnimalsEnzyme InhibitorsRats WistarSalinebusiness.industryEye dropGeneral MedicineFree Radical Scavengersmedicine.diseaseAcetylcysteineRatsOphthalmologyEye Burnsmedicine.anatomical_structureTreatment OutcomeAnesthesia030221 ophthalmology & optometryCorticosteroidDrug Therapy CombinationOphthalmic Solutionsbusinessmedicine.drugEuropean journal of ophthalmology
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Management of chronic hepatitis C in childhood: The impact of therapy in the clinical practice during the first 2 decades

2011

Background and aim: Treatment of chronic hepatitis C in children is controversial and its role in the clinical practice is unknown. We retrospectively investigated the impact of treatment in a large cohort of children with chronic hepatitis C over the past 20years. Methods: 376 hepatitis C virus RNApositive children were recruited consecutively in five Italian centres since 1990and followed for1–17years. Results: 86 (23%)subjects were treated: 73 with recombinant interferon alone and 13 with pegylated-interferon and ribavirin. Sustained clearance of hepatitis C virus RNA was observed in 25%of the former, in 92%of the latter and in 9% of untreated cases(p < 0.001). Loss of viraemia was re…

Malemedicine.medical_specialtyAdolescentGenotypeCombination therapyHepatitis C virusNatural historyCHILDRENHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsTHERAPYPolyethylene Glycolschemistry.chemical_compoundChronic hepatitisHepatitis C virus RNAInternal medicineRibavirinmedicineHumansChildRetrospective StudiesHepatologyHepatitis C virusbusiness.industryRibavirinGastroenterologyInfantInterferon-alphaCHRONIC HEPATITISHepatitis C ChronicRecombinant ProteinsTreatmentNatural historyClinical PracticeSustained virological responseChildren; Hepatitis C virus; Natural history; Sustained virological response; TreatmentchemistryViral replicationChild PreschoolHCVImmunologyRNA ViralDrug Therapy CombinationFemaleInterferonsbusinessDigestive and Liver Disease
researchProduct

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

2010

Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b plus RBV in children.Children and adolescents ages 3-17 years were treated with PEG-IFN alfa-2b (60microg/m(2)/week) plus RBV (15mg/kg/day). The duration of therapy was 24 weeks for genotype (G) 2 and G3 patients with low viral load (600,000IU/ml) and 48 weeks for G1, G4, and G3 with high viral load (or=600,000IU/ml). The primary end point was sustained virologic response (SVR), defined as undetectable hepatitis C vi…

Malemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundChild DevelopmentPegylated interferonInternal medicineDrug Resistance ViralRibavirinmedicineHumansChildAdverse effectHepatologybusiness.industryRibavirinBody WeightInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseBody HeightRecombinant ProteinsTreatment OutcomechemistryChild PreschoolImmunologyPeginterferon alfa-2bDrug Therapy CombinationFemaleViral hepatitisbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders.

2013

<b><i>Background/Aim:</i></b> Combined growth hormone (GH) and insulin therapy is rarely prescribed by pediatric endocrinologists. We investigated the attitude of Italian physicians to prescribing that therapy in the case of short stature and type-1 diabetes (T1DM). <b><i>Methods:</i></b> A questionnaire was sent and if a patient was identified, data on growth and diabetes management were collected. <b><i>Results:</i></b> Data from 42 centers (84%) were obtained. Of these, 29 centers reported that the use of combined therapy was usually avoided. A total of 17 patients were treated in 13 centers (GH was started before T1…

Malemedicine.medical_specialtyAdolescentGrowth hormone; Insulin therapy; GH deficiency; Type-1 diabetes; Turner syndromeTurner syndromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType-1 diabeteseducationDwarfismTYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSGrowth hormoneSettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyInsulin resistancePharmacotherapySurveys and QuestionnairesInternal medicineDiabetes mellitusgrowth hormone treatment; TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSTurner syndromemedicineHumansHypoglycemic AgentsInsulinChildDwarfism PituitaryGrowth hormoneGrowth DisordersGH deficiencyType 1 diabetesHuman Growth Hormonebusiness.industryInsulingrowth hormone treatmentmedicine.diseaseDiabetes Mellitus Type 1EndocrinologyChild PreschoolPediatrics Perinatology and Child HealthInsulin therapyDrug Therapy CombinationFemaleInsulin Resistancebusiness
researchProduct

Combined creatine and sodium bicarbonate supplementation enhances interval swimming.

2004

This study examined the effect of simultaneous supplementation of creatine and sodium bicarbonate on consecutive maximal swims. Sixteen competitive male and female swimmers completed, in a randomized order, 2 different treatments (placebo and a combination of creatine and sodium bicarbonate) with 30 days of washout period between treatments in a double-blind crossover procedure. Both treatments consisted of placebo or creatine supplementation (20 g per day) in 6 days. In the morning of the seventh day, there was placebo or sodium bicarbonate supplementation (0.3 g per kg body weight) during 2 hours before a warm-up for 2 maximal 100-m freestyle swims that were performed with a passive recov…

Malemedicine.medical_specialtyAdolescentPassive recoveryPhysical Therapy Sports Therapy and RehabilitationCreatinePlacebochemistry.chemical_compoundAnimal scienceDouble-Blind MethodmedicineBlood lactateHumansOrthopedics and Sports MedicineSwimmingMorningAnalysis of VarianceSodium bicarbonateCross-Over Studiesbusiness.industryGeneral MedicineCreatineCrossover studySurgerySodium BicarbonatechemistryDietary SupplementsPhysical EnduranceDrug Therapy CombinationFemaleAnalysis of variancebusinessJournal of strength and conditioning research
researchProduct